Drug Profile
Omeprazole controlled release - Avadel Pharmaceuticals
Alternative Names: Omeprazole XLLatest Information Update: 06 Nov 2021
Price :
$50
*
At a glance
- Originator Flamel Technologies
- Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiulcers; Gastric antisecretories; Small molecules
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastro-oesophageal reflux
Most Recent Events
- 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux in Europe (PO, Controlled release)
- 10 Jan 2008 Phase-I clinical trials in Gastro-oesophageal reflux in Europe (PO)